Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Manitoba

$17,500.00

Generation and characterization of a bivalent replication-competent vaccine against Ebola virus and human immunodeficiency virus

EF 2014-15

Résumé
The current Ebola outbreak and the long-lived HIV pandemic are two significant threats to global public health. The devastating impact of these viruses can especially be seen in Africa, where succumbing to the effects of either Ebola or HIV is a grim reality. On one hand, Ebola causes a highly lethal hemorrhagic fever, for which there are no licensed treatments and vaccines. On the other hand, HIV infects and destroys CD4+ T cells, causing acquired immunodeficiency syndrome (AIDS), which leads to deadly secondary infections. Developing effective vaccines and treatments for HIV has been extremely challenging because of its high mutation rate. We propose to develop a vaccine that is effective against both Ebola and HIV. The vaccine will consist of a live-attenuated HIV in which the surface protein is replaced by the Ebola surface protein. Unlike wild type HIV, this vaccine will be unable to infect CD4+ T cells, and therefore, will not cause AIDS in humans. The Ebola envelope protein will instead allow the vaccine to target and activate macrophages and dendritic cells to promote immune responses so that the body will be prepared to fight an Ebola or HIV infection. An important benefit of this approach is that this live-attenuated vaccine will evolve and gain mutations over time, an important factor in protecting against different HIV strains. This project will result in the development of an economical, dual vaccine in the ongoing battles against Ebola and HIV.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331369
Name
Mendoza Emelissa J
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Generation and characterization of a bivalent replication-competent vaccine against Ebola virus and human immunodeficiency virus
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aids; Cell-Mediated Immunity; Ebola; Hemorrhagic Fever; Hiv; Humoral Immunity; Immune Response; Prevention; Prophylaxis; Vaccine
Abstract
The current Ebola outbreak and the long-lived HIV pandemic are two significant threats to global public health. The devastating impact of these viruses can especially be seen in Africa, where succumbing to the effects of either Ebola or HIV is a grim reality. On one hand, Ebola causes a highly lethal hemorrhagic fever, for which there are no licensed treatments and vaccines. On the other hand, HIV infects and destroys CD4+ T cells, causing acquired immunodeficiency syndrome (AIDS), which leads to deadly secondary infections. Developing effective vaccines and treatments for HIV has been extremely challenging because of its high mutation rate. We propose to develop a vaccine that is effective against both Ebola and HIV. The vaccine will consist of a live-attenuated HIV in which the surface protein is replaced by the Ebola surface protein. Unlike wild type HIV, this vaccine will be unable to infect CD4+ T cells, and therefore, will not cause AIDS in humans. The Ebola envelope protein will instead allow the vaccine to target and activate macrophages and dendritic cells to promote immune responses so that the body will be prepared to fight an Ebola or HIV infection. An important benefit of this approach is that this live-attenuated vaccine will evolve and gain mutations over time, an important factor in protecting against different HIV strains. This project will result in the development of an economical, dual vaccine in the ongoing battles against Ebola and HIV.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mendoza, Emelissa J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~